Erythropoietin Resistance Index and the Affecting Factors in Children with Peritoneal Dialysis

Author:

Pınarbaşı Ayşe Seda,Dursun Ismail,Günay Neslihan,Baatar Batsaikhan,Yel Sibel,Dursun Jale,Balaban Aynur Gencer,Poyrazoğlu Muammer Hakan,Düşünsel Ruhan

Abstract

<b><i>Background:</i></b> Erythropoiesis-stimulating agents (ESAs) are used to treat anemia in CKD. Erythropoietin resistance index (ERI) is a useful tool used to evaluate the response to ESAs. In this study, we aimed to evaluate the causes of high ERI in children undergoing peritoneal dialysis (PD). <b><i>Method:</i></b> Patients who had been on PD for at least 1 year were included in this retrospective study. Demographic characteristics, residual kidney function (RKF), adequacy of dialysis, peritoneal glucose exposure, the number and reason for hospitalization, and medications were recorded. Anemia and laboratory parameters that may affect anemia were noted by taking the average of laboratory values in the last follow-up year (time-averaged). The weekly ESA dose was proportioned to the annual average hemoglobin value and body weight to calculate the ERI in terms of U/kg/week/g/dL. <b><i>Results:</i></b> A total of 100 patients were included in the study. The mean ESA dose and ERI value were 119.8 ± 66.22 U/kg/week and 13.01 ± 7.52 U/kg/week/g/dL, respectively. It was determined that the patients &#x3c;5 years of age have very high ERI value, and these patients need 2 times more ESA than those &#x3e;10 years of age. Absence of RKF, large number of hospitalization, and ACEI use were also found to affect the ERI value negatively. <b><i>Conclusion:</i></b> We demonstrate that the most important factor affecting ERI value is young age. We also reveal that absence of RKF, large number of hospitalization, and ACEI use are also important variables affecting the ERI value.

Publisher

S. Karger AG

Subject

Nephrology,Hematology,General Medicine

Reference29 articles.

1. Abdelkader RH. Quality of life is correlated to anemia in children and adolescent undergoing hemodialysis. Glob J Health Sci. 2018;10(10):103–12.

2. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73–8.

3. Bamgbola OF. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int. 2011;80(5):464–74.

4. Bynum JP, Zachary A, Ness PM, Luo X, Bagnasco S, King KE, et al. Transfusion of leukoreduced blood products and risk of antibody-mediated rejection of renal allografts. Transfusion. 2018;58(8):1951–7.

5. Okazaki M, Komatsu M, Kawaguchi H, Tsuchiya K, Nitta K. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients. Blood Purif. 2014;37(2):106–12.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3